Lana Dinic

Private Equity Investor chez Flagship Pioneering

Profil

Lana joined Pioneering Medicines in 2020 and is responsible for providing scientific and business insights into the overall portfolio strategy as well as project management of key programs.
Before joining Pioneering Medicines, Lana worked at Kintai, a Flagship company, where she was Chief of Staff to the CEO, driving critical operational and strategic initiatives.
Prior to Kintai, Lana spent 7 years at L.E.K.
Consulting in their Boston and London offices.
There she led international teams defining and executing corporate strategies, evaluating market opportunities and commercial strategy, and optimizing operations for pharmaceutical and biotech clients.
In addition, she established a broad range of initiatives to integrate the Global Life Sciences practice and developed best practices to advance the firm’s capabilities.
Lana earned her Ph.D.
in Professor Phyllis Kanki’s Lab in the Department of Immunology and Infectious Diseases at Harvard.
There, working with the Harvard-PEPFAR program, she had the opportunity to help build a molecular diagnostics lab and train clinical laboratory scientists in Nigeria and Tanzania.
Her graduate thesis focused on tuberculosis drug resistance and mycobacterial disease diversity in HIV patients in Nigeria.
Prior to graduate school Lana did research on RNA interference in the Tuschl Lab at Rockefeller University.
She holds a B.A.
in Biochemistry from Mount Holyoke College.

Postes actifs de Lana Dinic

Sociétés	Poste	Début
Flagship Pioneering	Private Equity Investor	01/01/2020